<p>The present invention relates to novel endogenous variants of erythropoietin (EPO) and their use for treatment or prevention of a condition associated with tissue damage due to cell death (apoptosis, necrosis) and inflammtion, in particular for neuroprotection, e.g. treatment of acute (for example stroke) and chronic disease (for example ALS) of the nervous system.</p>
申请公布号
AU2006245916(B2)
申请公布日期
2012.03.15
申请号
AU20060245916
申请日期
2006.05.15
申请人
CHARITE UNIVERSITATSMEDIZIN-BERLIN
发明人
DIRNAGL, ULRICH;BONNAS, CHRISTEL;PRILLER, JOSEF;MEISEL, ANDREAS